Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
86328 trials found · Page 70 of 4317
-
Daily pill shows promise in helping kids with dwarfism grow
Disease control CompletedThis is a Phase 3, multicenter, double-blind, randomized, placebo-controlled study to evaluate the efficacy and safety of infigratinib in children and adolescents with achondroplasia (ACH) who have completed at least 26 weeks of participation in the QED-sponsored study PROPEL (QB…
Phase: PHASE3 • Sponsor: QED Therapeutics, a BridgeBio company • Aim: Disease control
Last updated Apr 09, 2026 19:32 UTC
-
Global race for better mesothelioma treatment: new drug combo enters final testing phase
Disease control Recruiting nowThis is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleur…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
Experimental cell therapy aims to fight Tough-to-Treat blood cancer
Disease control OngoingThis study will have two Phases: Phase 1a and Phase 1b. The goal of Phase 1a of this clinical study is to learn more about the safety, tolerability and dosing of study drug KITE-197, in participants with relapsed or refractory large B-cell lymphoma (r/rLBCL). The goal of Phase 1b…
Phase: PHASE1 • Sponsor: Kite, A Gilead Company • Aim: Disease control
Last updated Apr 07, 2026 14:35 UTC
-
Scientists test Patient's own supercharged immune cells to fight tough melanoma
Disease control Completed20 participants are expected to be enrolled for the Phase Ib clinical trial,this trail is expected to be finished in 20 months.
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Apr 17, 2026 16:10 UTC
-
Radiation blast before supercharged cells: new hope for tough lymphomas
Disease control Recruiting nowThis is a phase 2, single-arm, open-label study to evaluate the safety and efficacy of comprehensive bridging radiation therapy prior to CD19 CAR T-cell therapy for large B-cell lymphoma patients with bulky disease, defined as any lesion ≥5 cm.
Phase: PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Mar 31, 2026 12:10 UTC
-
New 'Living Drug' trial seeks to reboot immune system to fight cancer
Disease control OngoingThe goal of this multicenter study is to test JNJ-90009530 in Relapsed or Refractory Non-Hodgkin Lymphoma Patients. The main questions the study aims to answer are: * can a dose of JNJ-90009530 be determined that is safe and well tolerated by patients. * will JNJ-90009530 help p…
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
New hope for kids with tough cancers: experimental cell therapy trial opens
Disease control Recruiting nowThe goal of this clinical trial is to determine the maximum tolerated dose (MTD) and recommended Phase II dose (RP2D) of allogeneic expanded γδ T cells when delivered with Dinutuximab, temozolomide, irinotecan, and zoledronate in children with refractory or recurrent neuroblastom…
Phase: PHASE1 • Sponsor: Emory University • Aim: Disease control
Last updated Apr 15, 2026 16:15 UTC
-
New hope for babies with leukemia: experimental treatment targets cancer cells
Disease control Recruiting nowThe purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia cells outer membrane.
Phase: PHASE1, PHASE2 • Sponsor: Tanja Andrea Gruber • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Ghana launches massive Community-Wide attack on malaria
Disease control Recruiting nowPrevious malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT) study, more than 75% of people in target communities were reached, leading to a 24% reduction in asymp…
Phase: NA • Sponsor: Noguchi Memorial Institute for Medical Research • Aim: Disease control
Last updated Mar 30, 2026 14:30 UTC
-
New hope for tough breast cancer: SKB264 trial targets Chemo-Resistant tumors
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of SKB264 in patients with unresectable locally advanced, recurrent, or metastatic HR+/HER2- breast cancer.
Phase: PHASE3 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Apr 25, 2026 10:42 UTC
-
New drug combo trial offers hope for advanced breast cancer patients
Disease control Recruiting nowThe goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palb…
Phase: PHASE3 • Sponsor: LeonaBio • Aim: Disease control
Last updated Apr 22, 2026 15:58 UTC
-
New targeted drug trial offers hope for Tough-to-Treat pancreatic cancer
Disease control Recruiting nowPatients with other advanced solid tumors (excluding NSCLC and CRC) who have progressed after prior systemic therapy or are intolerant and lack satisfactory alternative treatment options, aiming to evaluate the efficacy and safety of Glecirasib in these patients.
Phase: PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
Targeted radiation therapy battles standard drug in fight against rare tumors
Disease control Recruiting nowLEVEL trial aims to demonstrate the higher efficacy of 177Lu-edotreotide over everolimus in patients with well to moderately differentiated neuroendocrine tumors of the lung and thymus who require systemic therapy. It is hypothesized that 177Lu-edotreotide may significantly incre…
Phase: PHASE3 • Sponsor: Grupo Espanol de Tumores Neuroendocrinos • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
Major trial tests new drug combo against standard treatment for advanced lung cancer
Disease control Recruiting nowThis is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progressio…
Phase: PHASE3 • Sponsor: Summit Therapeutics • Aim: Disease control
Last updated Mar 23, 2026 15:19 UTC
-
Trial aims to personalize and improve Pre-Surgery breast cancer treatment
Disease control Recruiting nowThe goal of this clinical trial is to compare trastuzumab deruxtecan (T-DXd) to standard preoperative treatment in patients with non-metastatic HER2-positive breast cancer. The main questions it aims to answer are: * is T-DXd more effective than standard preoperative treatment? …
Phase: PHASE2 • Sponsor: Karolinska University Hospital • Aim: Disease control
Last updated Mar 24, 2026 12:01 UTC
-
Life-or-Death trial: can common steroids save lives in sudden lung crisis?
Disease control Recruiting nowAcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with a poor prognosis, with a 3-month mortality rate of over 50%. To date, no treatment has been proven to be effective in AI-FPI. The interest of glucocorticoids is controversial and needs to be confirmed…
Phase: PHASE3 • Sponsor: Fondation Hôpital Saint-Joseph • Aim: Disease control
Last updated Mar 30, 2026 14:34 UTC
-
New drug duo targets aggressive colon cancer mutation in major trial
Disease control Recruiting nowThis is a multicenter, randomized, open-label, Phase 3 study
Phase: PHASE3 • Sponsor: Shanghai Kechow Pharma, Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:22 UTC
-
New hope for lymphoma patients Who've run out of options
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL).
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Liver pump trial aims to extend lives in advanced colon cancer
Disease control Recruiting nowThis phase III trial compares hepatic arterial infusion (HAI) (pump chemotherapy) in addition to standard of care chemotherapy versus standard of care chemotherapy alone in treating patients with colorectal cancer that has spread to the liver (liver metastases) and cannot be remo…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
New hope pill targets tough leukemia in returning patients
Disease control OngoingThe Phase I/II trial is to learn the safety, pharmacokinetics, and preliminary efficacy of BN104 taken once daily or twice daily in patients with acute lymphocytic leukemia or acute myeloblastic leukemia.
Phase: PHASE1, PHASE2 • Sponsor: Institut de Recherches Internationales Servier (I.R.I.S.) • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC